Clinical trial · Interventional
Effects of Zometa and Physical Activity on Bone Density in Women Receiving Chemotherapy for Breast Cancer
The Effects of Zoledronic Acid (Zometa) and Physical Activity on Bone Density in Women Receiving Chemotherapy for Breast Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the effect of zoledronic acid and physical activity on preventing bone loss in women aged 40 - 55 who are receiving chemotherapy for breast cancer. The primary objective is to compare the percent change in the lumbar spine bone mineral density (BMD) from baseline to 12 months for women who are randomized to either: Group A) intravenous zoledronic acid, oral calcium carbonate, and vitamin D, or Group B) a prescribed physical activity program, oral calcium carbonate and vitamin D.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Physical activity intervention | Behavioral | — | UNRESOLVED |
| Zoledronic acid | Drug | Zoledronic Acid | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Change in Bone Mineral Density from baseline to 12 months after beginning chemotherapy
Secondary outcomes (1)
- measure
- Quality of life
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 40 Years
- Maximum age
- 55 Years
Show eligibility criteria text
Inclusion Criteria: * Women with Stage I - II breast cancer * Ages 40 - 55 * Pre- or peri-menopausal * Within 1 month of beginning adjuvant or neoadjuvant chemotherapy * Baseline lumbar spine and total hip BMD \> -2.0 SD * Able to read and write English * Signed consent form Exclusion Criteria: * Previous treatment with bisphosphonates * Laboratory evidence of renal disease * Previous TRAM flap reconstructive surgery * Positive pregnancy test * Mental illness that precludes the patient from giving informed consent * Laboratory evidence of hepatic disease
References
Publications (2)
- RESULTSwenson KK, Nissen MJ, Anderson E, Shapiro A, Schousboe J, Leach J. Effects of exercise vs bisphosphonates on bone mineral density in breast cancer patients receiving chemotherapy. J Support Oncol. 2009 May-Jun;7(3):101-7. PMID 19507458
- DERIVEDAdams A, Jakob T, Huth A, Monsef I, Ernst M, Kopp M, Caro-Valenzuela J, Wockel A, Skoetz N. Bone-modifying agents for reducing bone loss in women with early and locally advanced breast cancer: a network meta-analysis. Cochrane Database Syst Rev. 2024 Jul 9;7(7):CD013451. doi: 10.1002/14651858.CD013451.pub2. PMID 38979716